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Abstract
Background: In recent decades, increased attention has been focused on the impact of disabilities and medicinal drug use
on road safety. The aim of our study was to investigate the association between prescription medicines and the risk of road
traffic crashes, and estimate the attributable fraction.
Methods and Findings: We extracted and matched data from three French nationwide databases: the national health care
insurance database, police reports, and the national police database of injurious crashes. Drivers identified by their national
health care number involved in an injurious crash in France, between July 2005 and May 2008, were included in the study.
Medicines were grouped according to the four risk levels of the French classification system (from 0 [no risk] to 3 [high risk]).
We included 72,685 drivers involved in injurious crashes. Users of level 2 (odds ratio [OR] =1.31 [1.24–1.40]) and level 3 (OR
=1.25 [1.12–1.40]) prescription medicines were at higher risk of being responsible for a crash. The association remained after
adjustment for the presence of a long-term chronic disease. The fraction of road traffic crashes attributable to levels 2 and 3
medications was 3.3% [2.7%–3.9%]. A within-person case-crossover analysis showed that drivers were more likely to be
exposed to level 3 medications on the crash day than on a control day, 30 days earlier (OR =1.15 [1.05–1.27]).
Conclusion: The use of prescription medicines is associated with a substantial number of road traffic crashes in France. In
light of the results, warning messages appear to be relevant for level 2 and 3 medications and questionable for level 1
medications. A follow-up study is needed to evaluate the impact of the warning labeling system on road traffic crash
prevention.
Please see later in the article for the Editors’ Summary.
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The association between the use of benzodiazepines and the risk
of road traffic crashes has now been documented with consistent
results in several studies [1–13], but the effect of other medicines
has been less assessed and results of available studies are often
inconsistent [14]. This lack of assessment is particularly true for
opioids [2,8,9,12,15,16] and antidepressants [1,12,16,17]. Psycho-
active medicines may impair driving abilities owing to their action
on the central nervous system (e.g., sedation in the morning
following administration of a hypnotic), whereas other medicines
may affect psychomotor functions by their action on physiological
functions (e.g., hypoglycaemic seizures related to diabetic
treatment) or because of centralised side effects (e.g., the
depressant potential of carisoprodol on the central nervous
system). In the European Union, it is mandatory for pharmaceu-
tical companies to provide data about the effects of a medicine on
the ability to drive and to use machinery prior to the medicine
being allowed on the market. In 2003, the European Medicine
Agency requested the standardized classification of medicines
according to four levels of driving impairment risk, from level 0 (no
or negligible risk) to level 3 (major risk), in order to provide health
care professionals and patients with full information on the effects
of medicines on driving abilities. The European DRUID project
(Driving Under the Influence of Drugs, alcohol and medicines)
identified 16 classification systems worldwide [18]. In 2006, the
International Council on Alcohol, Drugs and Traffic Safety
(ICADTS) proposed a medication classification system on the basis
of the Belgium, Spanish, and French classification systems. In
France, a multidisciplinary group of experts was appointed to
classify all medicines according to four levels of risk in terms of
their effect on driving performance [19]. A graded pictogram was
designed to be printed on the outer packaging of all level 1 to 3
medicines (Figure 1). Pharmaceutical companies gradually imple-
mented this policy from 2005 to 2008. Level 1, 2, and 3
medications are labeled with instructions that are relevant to
driving for patients. The aim of our study was to estimate the
association between medicine use, as estimated using prescribed
medicine dispensation data from a health care reimbursement
database, and the risk of injurious road traffic crashes, as well as
the fraction of crashes attributable to medicine use in France.
Methods
Ethics Statement
This study was approved by the French Data Protection
Authority.
Data Sources
The study used three databases: the national health care
insurance database, and two police databases referring to the same
road traffic crash events but with different format and content.
Police reports. French police forces are required to fill out a
police report for each injurious crash occurring in the country
(about 70,000 reports each year). For some of the drivers involved
in these injurious road traffic crashes, the national health care
number (national ID) is recorded in the police report and can later
be matched with medication dispensing records in the health care
insurance database. Police reports are scanned and stored as
image files. All available police reports in France were gathered
over the study period.
National police database of injurious road traffic
crashes. Police forces also collect details on each injurious
crash event, which are stored in the national police database of
injurious crashes (Bulletins d’Analyse d’Accident Corporel
[BAAC]). This standardized database contains descriptive
variables on the crash characteristics, the vehicles, and the
people involved in the crash. Police forces also conduct
additional investigations regarding injury severity from hospital
records and categorize the people involved into four groups:
unhurt, slightly injured, seriously injured (hospitalized more than
24 h), or killed (in the 30 d following the crash). All drivers
involved in a road traffic crash are supposed to be tested for the
presence of alcohol using a breath test. If this test is positive
($0.5 g/l), the driver refuses to take the test, or the severity of the
crash makes the test impossible, then the blood alcohol
concentration is measured. If the breath test is negative, then
the driver is registered as not being under the influence of alcohol.
Missing data on alcohol impairment correspond to the following
situations: the result of the blood measurement was unknown at
the time of data entry in the database; the blood measurement
could not be done (e.g., insufficient blood); the breath test was not
done by the police; the breath test was positive but the blood
alcohol concentration was not measured; or the breath test was
negative but it was not coded in the database.
Health care insurance database. The national health care
insurance database (Syste `me National d’Informations Inter
Re ´gimes de l’Assurance Maladie [SNIIR-AM]) covers the entire
French population (in 2008, 64,000,000 people) and includes data
on reimbursed prescription medicines. A record is entered into the
database each time a prescription medicine is dispensed to an
outpatient at the pharmacy, including the national ID, the date
dispensed, and the seven-digit code (CIP code) assigned to the
medicine at the time of its marketing authorization. Data on long-
term chronic diseases are also registered in this database, with the
International Classification of Diseases, 10th edition (ICD-10)
code), start, and end dates of the disease. In France, patients are
fully reimbursed for health care expenses, including medicines,
related to 30 recognized long-term chronic diseases [20].
National ID Extraction and Matching Procedures
The first step of the study was extracting and matching data
from the comprehensive French nationwide databases described
above. Drivers involved in an injurious crash in France, between
July 2005 and May 2008, were included through their national ID,
gender, and date of birth, as extracted from police reports. An
application, based on optical character recognition (OCR), was
developed to automatically extract, from the image files, the crash
date, an individual’s national ID, gender, and date of birth. The
extraction procedure was validated on a subsample of 293 police
Figure 1. French medication labeling system.
doi:10.1371/journal.pmed.1000366.g001
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implemented to match each individual whose ID was extracted
from police reports with the corresponding record from the
national police database of injurious crashes. Two records were
considered matched if six descriptive variables were in agreement.
If a pair had three or more discordant variables, it was considered
unmatched. For pairs with concordance for fewer than six
variables and more than three variables, a probabilistic linkage
method was developed [21]. When a decision could not be made
automatically, pairs were reviewed by hand. Data on reimbursed
medicines dispensed within 6 mo before the crash were obtained
by linking included drivers to the national health care insurance
database using their national ID, gender, and date of birth.
Confidentiality was ensured by using the personal information
anonymization function of the national health care insurance
system [22].
Medicines and Exposure Periods
Daily medication exposure was estimated for each pharmaco-
therapeutic class, according to the WHO Anatomical Therapeu-
tic Chemical (ATC) classification. Medication exposure was
calculated as starting one day after dispensing, and exposure
duration was estimated from median values reported within a
survey on medicine prescription in France [23]. This survey was
conducted among 800 practitioners, representative of French
physicians, three times a year, over a 7-d period. To ensure that
prescribed medicines were not a consequence of the crash,
medications dispensed on the crash day were not included in the
analysis. We studied all dispensed and reimbursed prescription
medicines grouped according to the French risk classification
system [24].
A multidisciplinary group of experts developed the four-level
risk classification system. The grading method analysed all
available data: pharmacodynamic and kinetic effects, individual
sensitivity, the conditions of use of each medicine, pharmacov-
igilance data, and experimental and crash study data [25]. This
classification system ranks the four levels of driving impairment
risk from level 0 (no or negligible risk) to level 3 (major risk). A
graded pictogram is printed on the outer packaging of all level 1 to
3 medicines, accompanied by a written warning (Figure 1): level 0,
medicines with no pharmacodynamic effect likely to alter the
ability to drive, according to current information (6,282 medi-
cines); level 1, medicines that do not generally impact on ability to
drive, but require patient information (1,190 medicines); level 2,
medicines that could affect the ability to drive and require medical
advice before use (1,601 medicines); level 3, medicines that are
known to affect the ability to drive during use (194 medicines).
Determining Crash Responsibility
Responsibility levels in the crash were determined by a
standardized method adapted from Robertson and Drummer
[26]. This method, recently validated in France using the national
police database of fatal crashes [27], takes into consideration the
different factors likely to reduce driver responsibility: road, vehicle
and driving conditions, type of accident, traffic rule obedience,
and difficulty of the task involved. A score is assigned to each
driver for each of these factors from 1 (favourable to driving) to 4
(not favourable to driving). The higher the sum of the scores, the
more unfavourable the driving conditions, and thus the more likely
it is that the driver will be considered not-responsible (nonrespon-
sible) for the crash. Drivers were further grouped into two levels of
crash responsibility: responsible (score ,15) or nonresponsible
(score $15).
This method of determining the driver’s crash responsibility was
approved by an independent expert responsibility evaluation
(kappa =0.71).
Analysis
Participant inclusion. Individuals whose police reports did
not contain their national ID were not included. Drivers were
censored at their first involvement in a road traffic crash in order
to mitigate the impact of previous crashes on medicine exposure.
We compared, by logistic regression, age, gender, injury severity,
vehicle type, crash location, type of police force filing the police
report, alcohol level, and responsibility status between included
and nonincluded individuals.
Responsibility analysis. The purpose of the responsibility
analysis is to compare exposure probabilities on the day of crash
between responsible drivers (cases) and nonresponsible drivers
(controls) [26]. This method ensures that both cases and controls
are selected from the same driving population.
Statistical analyses were conducted using logistic regression. The
associations between responsibility and age, gender, socioeconom-
ic category, year, month, day of week, time of day, location,
vehicle type, alcohol level, and injury severity were initially
investigated using bivariate analysis; associated variables were
included in the multivariate model when the p-value was less than
20% (Chi-squared test). This value was the case for all variables
except for the year of crash, which was forced into the model
because prescription patterns may have changed between the
2005–2006 and 2007–2008 periods. Further analyses adjusted for
the presence of long-term chronic diseases. We tested the
interactions between exposure and each of the adjustment
variables.
Attributable fractions were estimated from the adjusted odds
ratio (OR) estimates and the prevalence of exposure in responsible
drivers [28]. Confidence intervals (CIs) were computed using the
bootstrap method [29,30], estimated from the 2.5th and the 97.5th
percentiles of the distribution resulting from 500 simulations.
Case-crossover analysis. The case-crossover analysis
consisted of a pair-matched analytical approach to compare
medicine exposure during a period immediately before the crash
(case period) with exposure during an earlier period (control
period) for the same person [31]. We compared medicine
exposure on the crash day with medicine exposure on the
control day. The washout period between the case and control
periods prevents any residual effect of an exposure in the control
period on the case period. In France, the duration of a pharmacy-
dispensed treatment cannot usually exceed 30 d (almost without
exception, i.e., contraceptive pills), so the duration of the washout
period was determined at 30 d. ORs were estimated by conditional
logistic regression, using the PHREG procedure in SAS.
Data were analyzed using the SAS statistical software package,
version 9.0 (SAS Institute Inc.).
Results
Study Population
The validation study conducted on 293 police reports showed
that the national ID was recorded for 140 of the 455 drivers
involved (28%). The automatic optical character recognition
(OCR) software extracted 110 of these 140 national IDs
(extraction rate =79%). Matching with the police national
database of injurious crashes was possible for 90% of the IDs.
The driver inclusion rate was thus expected to be about 20%.
Results of the overall extraction and matching procedures for
the study are illustrated in Figure 2. We extracted 109,078
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available from July 2005 to May 2008, corresponding to any
individual involved in an injurious road traffic crash. Ninety
percent of these individuals were matched with a corresponding
record in the national police database of injurious crashes (72.8%
fitted on all variables, 14.0% were matched by the probabilistic
linkage method, and 3.1% manually). The linkage failed for 10%
of the individuals, because the ID corresponded either to a driver
involved in the crash but not captured in the national police
database, or to an individual not involved in the crash (e.g., a
witness, the owner of a vehicle involved).
This procedure led to the inclusion of 72,685 drivers (34,896
responsible and 37,789 nonresponsible drivers), i.e.,18.5% of the
392,169 drivers registered in the national police database of
injurious crashes. Baseline characteristics of the study population
are presented in Table 1. Injury severity was the main factor
associated with the probabilityo fb e i n gp a r to ft h es t u d y( O R
=3.43 [3.29–3.58] for seriously injured drivers and OR =2.67
[2.57–2.77] for slightly injured drivers), thus explaining higher
rates of inclusion for bicycle (OR =1.24 [1.16–1.33] and scooter
drivers (OR =1.09 [1.03–1.16]) and drivers involved in
nonurban accidents (OR =1.14 [1.10–1.18]), all of whom have
been consistently documented in the literature to be more
seriously injured. The inclusion rate was slightly lower for
responsible drivers than for nonresponsible drivers (OR =0.91
[0.88–0.94]).
Exposure to Medicines
Twenty seven percent (n=19,777) of the drivers included in the
study were exposed to at least one prescribed medicine on the
crash day. The proportion of drivers exposed to level 0, level 1,
level 2, and level 3 medicines were respectively 21.6%, 10.2%,
11.4%, and 2.7%. There were 13,167 drivers (18%) exposed to at
least one prescribed medicine of level 1, 2, or 3 (Table 2).
Table 3 shows the main pharmacotherapeutic drug classes used
on the crash day among level 2 and 3 medicines by ATC class
(third level of the ATC system).
When adjusted for variables found to be associated with
responsibility in the crash (age, gender, socioeconomic category,
year, month, day of week, time of day, location, vehicle type,
alcohol level, injury severity) and for medicines of others levels, the
use of at least one level 2 or level 3 medicine was associated with
the risk of being responsible for a crash (OR =1.31 [1.24–1.40]
and OR =1.25 [1.12–1.40]). The use of level 0 medicines was
associated with a decreased risk of being responsible for a crash
(OR =0.92 [0.88–0.97]). The risk of being responsible was not
significant for level 1 medicines (Table 4). The fraction of road
traffic crashes attributable to use of levels 2 and 3 medicines was
3.0% [2.4%–3.5%] and 0.7% [0.4%–0.9%], respectively. The
global fraction attributable to both level 2 and 3 medicines
(considering exposure to level 2 or level 3 medicines on the crash
day) was 3.3% [2.7%–3.9%]. The associations remained after
adjustment for long-term chronic diseases (OR =0.92 [0.88–0.97]
for level 0, OR =1.30 [1.22–1.38] for level 2, and OR =1.24
[1.11–1.39] for level 3). There was no interaction of medicine use
with alcohol consumption (p=0.84 for level 2 and p=0.23 for
level 3). The information on alcohol level was missing for 9,919
individuals (13.6%). Excluding these individuals from the univar-
iate analysis led to no significant change in estimated ORs. We did
not find any interaction between the use of level 2 or level 3
medicines and the adjustment variables.
Among level 2 medicines, the risk of being responsible for a
crash was significantly higher for drugs used in diabetes (A10),
antiepileptics (N03), psycholeptics (N05), psychoanaleptics (N06),
and other nervous system drugs (N07). However, after Bonferroni
correction for multiple testing, the association remained significant
for the last four classes only (Table 5). The Benjamini and
Yekutieli procedure based on the false discovery rate led to the
same conclusions. The OR for level 3 psycholeptics was similar to
the OR estimated for all level 3 medicines.
The risk of being responsible for a crash gradually increased
from 1.14 [1.06–1.22] for users of one medicine of level 2 or 3 to
1.88 [1.58–2.25] for users of more than three medicines of level
2 or 3 (Table 6). Results from the case-crossover analysis showed
Figure 2. Flowchart of the inclusion procedure. *The discrepancy between the number of police reports and the number of records in the
national police database of injurious crashes is explained by the fact that a small proportion of unavailable reports were being used for on-going
further legal investigations.
doi:10.1371/journal.pmed.1000366.g002
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3 medicines and the risk of road traffic crash. There was no
association with level 0, level 1, and level 2 medicines
(Table 7).
Discussion
We found evidence for an increased risk of being responsible for
a road traffic crash for users of prescribed medicines defined as
presenting a level 2 or level 3 risk of driving impairment according
to the French medication classification system. The fraction of
road traffic crashes attributable to levels 2 and 3 medicine use was
3.3% [2.7%–3.9%].
The study protocol planned for the inclusion of a large range of
descriptive variables related to the crash and to the drivers
involved. In particular, we were able to determine the responsi-
bility status of the driver in the crash and to adjust for key
confounding factors. The responsibility analysis is a real strength
of the study as it allows for the comparisons of cases and controls
that share the same characteristic of being drivers. In a previous
study on the impact of illegal drug consumption, using the same
national police database but limited to fatal crashes [27], the same
Table 1. Baseline characteristics.
Baseline Characteristics n Percent
Total individuals 72,685
Sex
Men 49,770 68.5
Women 22,915 31.5
Age (y)
,18 3,055 4.2
18–24 14,814 20.4
35–34 16,666 22.9
35–44 15,488 21.3
45–54 11,796 16.2
55–64 5,990 8.2
65–74 2,837 3.9
$75 2,039 2.8
Socioeconomic category
Higher managerial and professional
occupations
2,784 3.8
Intermediate occupations 24,984 34.4
Workers 11,887 16.4
Retired 6,449 8.9
Unemployed 3,021 4.2
Other/missing 16,014 22.0
Student 7,546 10.4
Vehicle type
Light vehicle 42,792 58.9
Bicycle 3,867 5.3
Scooter 10,099 13.9
Motorbike 10,458 14.4
Commercial vehicle 2,550 3.5
Heavy goods vehicle 1,342 1.9
Other 1,577 2.2
Injury severity
Unhurt 19,093 26.3
Slightly injured 26,327 36.2
Seriously injured 25,864 35.6
Killed 1,401 1.9
Alcohol (g/l)
,0.5 58,700 93.5
[0.5–0.8] 568 0.9
[0.8–1.2] 786 1.3
[1.2–2] 1,392 2.2
$2 1,320 2.1
Long-term chronic disease
No 61,698 84.9
Yes 10,987 15.1
doi:10.1371/journal.pmed.1000366.t001
Table 2. Number of exposed drivers on the crash day by
classification and number of medicines used.
n Medicines n Exposed drivers
Level 0 medicines 15,715 (21.6%)
a
n medicines of the level
16 , 9 1 7
23 , 7 5 7
32 , 1 6 1
41 , 2 3 3
.41 , 6 4 7
No medicine in higher level
a 6,610
Level 1 medicines 7,415 (10.2%)
b
n medicines of the level
15 , 6 8 1
21 , 3 6 1
33 1 5
44 9
.49
No medicine in higher level
a 4,432
Level 2 medicines 8,268 (11.4%)
b
n medicines of the level
15 , 1 0 2
22 , 0 2 9
37 4 5
42 5 3
.41 3 9
No medicine in higher level
a 6,753
Level 3 medicines 1,982 (2.7%)
b
n medicines of the level
11 , 7 2 4
22 3 4
32 3
41
No medicine in higher level
a 1,982
an drivers exposed to at least one medicine in the level and no medicine in any
higher level.
bExposed to at least one medicine of the risk level considered.
doi:10.1371/journal.pmed.1000366.t002
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independent expert evaluation of responsibility. Furthermore,
because the responsibility analysis relies on the assumption that
nonresponsible drivers are representative of the driving popula-
tion, the authors of the previous study validated the comparison of
a subset of the nonresponsible individuals with the driving
Table 3. Level 2 and level 3 pharmacotherapeutic classes used on the crash day.
ATC Class Level 2 Medicines Level 3 Medicines
Total 13,147 2,265
Alimentary tract and metabolism (A) 1,056 —
Insulins and analogues (A10A) 370 —
Blood glucose-lowering drugs, excluding insulins (A10B) 668 —
Cardiovascular system (C) 196 —
Antiadrenergic agents, centrally acting (C02A) 195 —
Musculo-skeletal system (M) 277 —
Muscle relaxants, centrally acting (M03B) 248 —
Nervous system (N) 10,870 2,265
Opioids (N02A) 1,935 2
Antimigraine preparations (N02C) 337 —
Antiepileptics (N03A) 1,053 —
Anti-Parkinson drugs (N04) 175 —
Antipsychotics (N05A) 804 8
Anxiolytics (N05B) 2,843 471
Benzodiazepine derivatives (N05BA) 2,362 471
Antidepressants (N06A) 3,122 —
Selective serotonin reuptake inhibitors(N06AB) 2,188 —
Hypnotics and sedatives (N05C) —1 , 7 8 4
Benzodiazepine derivatives (N05CD) — 295
Benzodiazepine-related drugs (N05CF) — 1,196
Hypnotics and sedatives in combination, excluding barbiturates (N05CX) — 293
Drugs used in addictive diseases (N07B) 443 —
Drugs used in alcohol dependence (N07BB) 69 —
Drugs used in opioid dependence (N07BC) 374 —
Antihistamines for systemic use (R) 327 —
Phenothiazine derivatives (R06AD) 216 —
Some drivers may have been exposed to several substances from the same pharmacological subgroup, explaining the difference with the number of exposed drivers
presented in Table 2.
doi:10.1371/journal.pmed.1000366.t003
Table 4. ORs for responsible road traffic crashes in users of prescribed medicines.
Medicine Level Exposed Drivers OR [95% CI]
a Exposed Drivers
b OR [95% CI]
c OR [95% CI]
d
Level 0 15,715 0.92 [0.88–0.95]*** 13,702 0.92 [0.88–0.97]* 0.92 [0.88–0.97]**
Level 1 7,415 0.96 [0.92–1.01] 6,478 0.96 [0.90–1.02] 0.95 [0.89–1.01]
Level 2 8,268 1.24 [1.19–1.30]*** 7,102 1.31 [1.24–1.40]*** 1.30 [1.22–1.38]***
Level 3 1,982 1.56 [1.42–1.71]*** 1,679 1.25 [1.12–1.40]*** 1.24 [1.11–1.39]**
Reference group, drivers not exposed to medicines of the risk level considered.
aCrude ORs.
bModel computed for the 62,766 drivers with no missing values for the adjustment variables.
cORs adjusted for age, gender, socioeconomic category, year, month, day of week, time of day, location, vehicle type, alcohol level, injury severity and other level
medicines.
dORs adjusted for age, gender, socioeconomic category, year, month, day of week, time of day, location, vehicle type, alcohol level, injury severity, long-term chronic
diseases, and other level medicines.
*p,0.01.
**p,0.001.
***p,0.0001.
doi:10.1371/journal.pmed.1000366.t004
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relationship found in our study between alcohol level and
responsibility is a further indirect validation of the method.
Importantly, responsibility levels were calculated independently of
alcohol and illicit drug use because of their potential interactions
with medicine use.
Medicine exposure was ascertained from computerized records
of reimbursed prescriptions filled at the pharmacy. These data
were not subject to underreporting, a major problem encountered
when medicine exposure data is self-reported [5]. On the other
hand, it is one of the study limitations that dispensing dates were
considered in this study as a surrogate for actual consumption. We
did not know whether the medicines were actually ingested or not.
Noncompliance, which we were not able to check, would therefore
result in exposure misclassification. Other studies using patient-
derived data and the same dispensation database showed that the
health care insurance data are reliable indicators of actual
exposure for medicines used over a long time frame, less so for
episodically used medicines [32]. We assumed that the exposure
period started on the day after dispensing, as medicine
dispensation on the day of crash may have been a consequence
of the crash. Another limitation was that exposure to nonpre-
scribed drugs can also not be estimated from the health care
insurance database. However, less than 15% of medicines sold in
France correspond to nonreimbursable medicines and most of
these products have either no or negligible influence on the ability
to drive.
The comparison between included drivers by means of their
national ID and nonincluded drivers showed that injury severity
was associated with the probability of being part of the study. Thus
severely injured drivers were more likely to be included than
slightly injured drivers. Killed drivers and uninjured drivers still
had lower inclusion rates. This finding can be explained by the fact
that injured drivers were more likely to be admitted to hospital so
their health care number was more frequently noted in the police
report. Thus, our study sample slightly overrepresented drivers
injured in more severe crashes.
After adjustment for crash and individual variables, including
exposure to other medicines, the risk of being responsible estimate
was reduced for level 3 medicines, but the association did remain
significant (from 1.56 [1.42–1.71] to 1.25 [1.12–1.40]). The crude
risk of being responsible measured for level 3 medicines was thus
partly related to these crash and individual variables and particularly
due to a co-consumption of alcohol and level 2 medicines.
The protective effect of level 0 medicines could be explained by
the treatment of those minor acute diseases that might lead to an
increased risk of being responsible for the crash. Indeed, a number
of specific physical and/or psychological conditions are likely to
influence driving ability.
Surprisingly, we found no interaction between alcohol level, as
reported by police forces, and medicine use, although alcohol is
known to potentiate the effects of some medicines. It should be
noted, however, that as the presence of alcohol is not always tested
for in drivers involved in slight-injury crashes, this variable might
be underestimated. Moreover, drivers who had a negative breath
test were not tested for blood alcohol concentration (the legal limit
in France is less than 0.5g/l). Information about illicit drug use was
not available in any database. The analysis was also unable to
adjust for driving exposure. Whilst on medication, some people
Table 5. ORs for responsible road traffic crashes in users of
prescribed medicines by ATC class.
Level 2
Exposed
Drivers
a OR [95% CI]
b
Drugs used in diabetes (A10) 795 1.20 [1.03–1.40]*
Antihypertensives (C02) 172 1.07 [0.78–1.47]
Muscle relaxants (M03) 219 0.82 [0.62–1.09]
Analgesics (N02)
c 1,845 1.04 [0.94–1.15]
Antiepileptics (N03) 755 1.41 [1.21–1.65]***
Anti-Parkinson drugs (N04) 125 1.15 [0.79–1.68]
Psycholeptics (N05)
d 2,566 1.27 [1.15–1.40]***
Psychoanaleptics (N06)
e 2,572 1.31 [1.19–1.44]***
Other nervous system drugs (N07)
f 369 1.46 [1.16–1.84]**
Antihistamines for systemic use (R06) 267 1.05 [0.81–1.35]
aModel computed for the 62,766 drivers with no missing values for the
adjustment variables.
bORs adjusted for age, gender, socioeconomic category, year, month, day of
week, time of day, location, vehicle type, alcohol level, injury severity, long-
term chronic diseases, and other medicines.
cIncluding opioids (n=1,585), other analgesics and antipyretics (n=22), and
antimigraine preparations (n=281).
dIncluding antipsychotics (n=558) and anxiolytics (n=2,250).
eIncluding antidepressants (n=2,509), psychostimulants (n=56), and
antidementia drugs (n=33).
fIncluding drugs used in alcohol dependence (n=51), drugs used in opioid
dependence (n=295), antivertigo preparations (n=7), and other nervous
system drugs (n=16).
*p,0.05 (nonsignificant after Bonferroni correction a (corrected) =0.05/
10=0.005).
**p,0.001.
***p,0.0001 (still significant after Bonferroni correction).
doi:10.1371/journal.pmed.1000366.t005
Table 6. ORs for responsible road traffic crashes by number
of level 2 and/or level 3 medicines used.
Number of Level 2/
Level 3 Medicines Exposed Drivers OR [95% CI]
a
0 55,264 Reference
1 4,259 1.14 [1.06–1.22]*
2 1,829 1.30 [1.17–1.43]**
3 817 1.86 [1.59–2.16]**
.3 597 1.88 [1.58–2.25]**
aORs adjusted for age, gender, socioeconomic category, year, month, day of
week, time of day, location, vehicle type, alcohol level, and injury severity.
*p,0.001 (still significant after Bonferroni correction).
**p,0.0001.
doi:10.1371/journal.pmed.1000366.t006
Table 7. Case-crossover analysis: ORs for road traffic crashes
in users of prescribed medicines.
Medicine Exposed Drivers
a OR [95% CI]
b
Level 0 4,047 1.02 [0.98–1.07]
Level 1 2,249 1.02 [0.96–1.08]
Level 2 3,131 1.00 [0.95–1.05]
Level 3 896 1.15 [1.05–1.27]*
aDrivers exposed in the case period and not exposed in the control period.
bOnly considering exposure to medicine of the highest level of risk.
*p,0.01.
doi:10.1371/journal.pmed.1000366.t007
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reduce their speed, pay more attention, or alter the road types that
they use. The present study therefore estimated the impact of
actual consumption and driving behaviors on the risk of road crash
among active drivers.
According to our results, the French risk classification seems
relevant regarding medicines classified as levels 2 and 3 of risk for
road traffic crashes. Even if the risk for level 2 and 3 medications is
similar, we believe that it is useful to differentiate these two levels.
The effects of level 2 medicines on driving abilities depends both
on the pharmacodynamics of the drug and on individual
susceptibility; medical advice is therefore needed to weigh the
potential risk for each individual. Various medicines are classified
as level 2. The risks found for psycholeptics (mainly anxiolytics)
and psychoanaleptics (mainly antidepressants) are concordant with
others studies [2,10–12,16,17]. The results for antiepileptics and
other nervous system drugs (in particular medicines used to treat
opioid dependence) are of interest and deserve further investiga-
tion. For some of the ATC classes in level 2, the association in the
responsibility analysis was not significant; however, the number of
drivers exposed to antihypertensives, muscle relaxants, anti-
Parkinson drugs, and antihistamines for systemic use was small.
On the other hand, despite a relatively large number of individuals
exposed to analgesics (including opioid analgesics), we found no
association with the risk of being responsible for a crash. With level
3 medicines, the pharmacodynamic effect is predominant so all
users are advised not to drive. The effects of level 1 medicines may
be so dependent on individual susceptibility that an effect on
driving abilities might be a rare event. Therefore, the relevance of
labeling level 1 medicines is questionable.
The respective roles of disease and the medicines used to treat
disease are difficult to disentangle. After adjustment for the
presence of a long-term chronic disease, results from the
responsibility analysis did not suggest an important confounding
effect of disease. In the case-crossover method, each individual is
his or her own control and confounding due to individual factors is
therefore eliminated, including fixed characteristics such as long-
term chronic diseases. Other studies have used this approach to
examine the relationship between medicines and the risk of injury
[1,12,33]. The use of level 3 medicines was found to be associated
with an increased risk of road traffic crash both in the
responsibility analysis and in the case-crossover analysis. However,
the risk associated with level 2 medicines in the responsibility
analysis (OR =1.31 [1.24–1.40]) disappeared in the case-
crossover analysis (OR =1.00 [0.95–1.05]). The risk of road
traffic crashes associated with chronic exposure to level 2
medicines cannot be assessed by a case-crossover design. Indeed,
an individual using a medicine throughout the study period would
be exposed on the crash date and on the control day. Our results
on level 2 medicines are therefore likely to be related to the impact
of chronic medicine consumption, i.e., mainly drugs used in
diabetes, opioids, antiepileptics, anxiolytics, and antidepressants.
On the other hand, hypnotics and sedatives, mainly representing
level 3 medicines, can be used on an acute basis and their impact
on road traffic crashes are detected with the case-crossover
analysis.
Our study provides evidence of the contribution of medicines to
the risk of road traffic crashes. Improving driver behaviour is one
of the challenges for improving road safety. Providing patients
with proper information on the potential effect of medicines on
their ability to drive is the main objective of drug and risk
classifications such as the French framework. The European
Union is currently aiming to harmonise drug classification systems,
using a reliable methodology based on scientific evidence. This
epidemiological study provides sound evidence for consideration
in such an endeavour. A follow-up study is now needed to evaluate
the effect of the French medication labeling system on the
prevention of road traffic crashes.
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About 1.3 million people die each year on the world’s road.
90% of road traffic deaths occur in developing countries,
with pedestrians, cyclists, and users of two-wheel vehicles
(scooters, motorbikes) the most vulnerable road users.
Although the use of prescribed benzodiazepines has already
been documented to be associated with road traffic
accidents in industrialized countries, the effects of other
medicines have not been well studied or have inconsistent
results (for example opioids and antidepressant medica-
tions). In the European Union, it is mandatory for pharma-
ceutical companies to provide data about the effect of a
medicine on ability to drive. In France, a multidisciplinary
group of experts was appointed to classify all medicines into
four levels of risk (from level 0, no or negligible risk, to level
3, major risk), in terms of their effect on driving performanc-
es. In 2006, the International Council on Alcohol, Drugs and
Traffic Safety proposed a classification list similar to the
French classification system.
Why Was This Study Done? There is a pressing need to
understand the association between prescribed medicines
and the risk of road traffic crashes and also to have a more
accurate picture of the fraction of road traffic crashes that are
attributable to the use of prescribed medicines. This large
French study aimed to advance knowledge in this important
area.
What Did the Researchers Do and Find? The researchers
used three data sources to find the information they needed:
the national health care insurance database (which covers
the whole French population and includes data on
reimbursed prescription medicines), police reports, and the
national police database of injurious road traffic crashes.
Drivers involved in road traffic crashes (identified by their
national healthcare number) between July 2005 and May
2008 were included in the study. The researchers used a
statistical model to conduct a responsibility analysis, which
determined factors associated with each driver responsible
for the road traffic crash and each driver who was not
responsible (controls). In addition, the researchers compared
medicine exposure during a period immediately before the
crash (case period) with exposure during an earlier period
(control period) for each driver involved in a crash. The
researchers retrieved data on reimbursed medicines,
dispensed within six months of the road traffic crash, by
linking included drivers to the national health care insurance
database using their national ID, gender, and date of birth
and grouped all prescribed medicines according to the four
risk levels of the French classification system.
During the study period, 72,685 drivers involved in injurious
road traffic crashes were included. The researchers found
that drivers who had been prescribed level 2 and level 3
medicines were at higher risk (odds ratio 1.31 and OR 1.25,
respectively) of being responsible for the road traffic crash,
an association that remained after the researchers adjusted
for the presence of chronic diseases. Furthermore, the
researchers found that the fraction of road traffic crashes
attributable to the use of (prescriptions for) level 2 and 3
medicines was 3.3% and that drivers were more likely to be
exposed to level 3 medicines on the day of the road traffic
crash than on a control day.
What Do These Findings Mean? This study provides
strong evidence for the contribution of medicines to the risk
of experiencing a road traffic crash. The French drug risk
classification scheme seems accurate for medicines classified
as levels 2 and 3 of risk for road traffic crashes. The effect on
driving abilities of level 2 medicines depends both on the
pharmacodynamics of the drug and on individual suscepti-
bility, whereas for level 3 medicines, the pharmacodynamic
effect seems to be predominant. The effects of level 1
medicines seem to be so dependent on individual sus-
ceptibility that effects on driving abilities are rare, which
raises questions about the relevance of the labels for these
medicines. However, some limitations with the study
methodology might affect the interpretation of these find-
ings. For example, the researchers used dispensing dates for
medications as a surrogate for ingestion and were not able
to check for noncompliance.
However, this study provides some of the strongest evidence
to date of the need for health care workers to provide
patients with proper information on the potential effect of
any medicine that they are prescribed (or take) on their
driving abilities.
Additional Information Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000366.
N The World Health Organization (WHO) provides informa-
tion on road traffic accidents
N Two Web sites provide information for drivers about drugs
that could affect their ability to drive
N The US National Institute on Drug Abuse of the National
Institutes of Health has an information sheet on ‘‘drugged
driving’’
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